Page last updated: 2024-08-21

quinazolines and Local Neoplasm Recurrence

quinazolines has been researched along with Local Neoplasm Recurrence in 335 studies

Research

Studies (335)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.30)18.2507
2000's115 (34.33)29.6817
2010's197 (58.81)24.3611
2020's22 (6.57)2.80

Authors

AuthorsStudies
Ahn, BC; Cho, BC; Heo, SG; Hong, MH; Kim, HR; Lee, JH; Lim, SM1
Baldanti, F; Campanini, G; Cassaniti, I; Fratini, A; Girelli, F; Meini, A; Novazzi, F; Palumbo, L; Paolucci, S; Plebani, A; Tebaldi, A1
Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T1
Alessandrino, EP; Baldanti, F; Bernasconi, P; Binaschi, L; Borsani, O; Caldera, D; Cassinelli, G; Colombo, AA; Ferretti, VV; Gabanti, E; Lilleri, D; Sciarra, R; Zavaglio, F1
Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V1
Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J1
Armstrong, A; Bliss, JM; Brunt, AM; Bundred, N; Cameron, DA; Cramer, A; Cutress, RI; Dodwell, D; Emson, MA; Evans, A; Hanby, A; Hartup, SM; Horgan, K; McIntosh, SA; Miller, SE; Morden, JP; Naik, J; Narayanan, S; Ooi, J; Porta, N; Rakha, EA; Shaaban, AM; Skene, AI1
Batlevi, C; Biggar, E; Espeleta, JA; Kumar, A; Lam, HY; Matasar, M; Nichols, C; Owens, C; Qiu, A; Qualls, D; Salles, G; Seshan, V; Subzwari, S; Whiting, K; Younes, A1
Brown, J; Chapman, J; Diaz, JP; Dymond, M; Ghamande, S; Kendrick, J; Kumar, S; Lee, JM; Liu, JF; Lowe, ES; Milenkova, T; Moore, RG; Park, MS; Slomovitz, BM; Tewari, KS1
Childs, BH; Fukuhara, N; Garcia-Vargas, J; Hatake, K; Iriyama, C; Kamezaki, K; Kuroda, J; Kusumoto, S; Makita, S; Maruyama, D; Masuda, S; Minami, H; Nagai, H; Suehiro, Y; Terao, Y; Tobinai, K; Tsujino, T; Tsukamoto, N; Uchida, T; Yanada, M; Yasuda, M1
Cheng, Y; Song, R; Zheng, T1
Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E1
Chen, Y; Gubat, JA; Jia, Q; Li, Y; Liu, M; Min, L; Sun, C; Wang, X; Yang, J; Zhang, X; Zhu, C1
Bighin, C; Blondeaux, E; Cardinali, B; Del Mastro, L; Ferreira, AR; Fontana, A; Fregatti, P; Lai, A; Lambertini, M; Minuti, G; Montemurro, F; Mura, S; Poggio, F; Poletto, E; Puglisi, F; Sini, V; Sottotetti, F1
Gelmon, KA; Tesch, ME1
Bedir, S; Celik, E; Cikman, DI; Degerli, E; Demirci, NS; Demirelli, FH; Derin, S; Karadag, M; Oruc, K; Oztas, NS; Samanci, NS1
Arthur-Darkwa, E; Burnett, E; Counsell, N; El-Khouly, F; Elyashiv, O; Farrelly, L; Feeney, A; Gourley, C; Jayson, GC; Ledermann, J; Macdonald, I; Mileshkin, L; Neto, A; Nicum, S; Parmar, G1
Kim, JS; Kim, SJ; Kim, T; Kim, WS; Koh, Y; Moon, JH; Park, GS; Park, J; Shin, HJ; Yang, DH; Yhim, HY1
Collins, L; Dobbie, S; Dunn, R; Holmes, J; Mansouri, A; McGregor, N; Nicum, S1
Childs, BH; Dreyling, M; Follows, GA; Garcia-Vargas, J; Hiemeyer, F; Mollica, L; Nagler, A; Özcan, M; Panayiotidis, P; Santoro, A; Stevens, D; Trevarthen, D; Zinzani, PL1
Deane, E; Embleton-Thirsk, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Oza, A; Parmar, MKB; Perren, TJ; Popoola, B; Rustin, GJS; Swart, AM; Vaughan, M1
Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X1
Akamatsu, H; Daga, H; Harada, H; Hasegawa, Y; Hayashi, H; Kato, T; Kim, YH; Murakami, H; Nakagawa, K; Nishimura, Y; Shimizu, J; Tokunaga, S; Yamamoto, N1
Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G1
Anne Zujewski, J; Azim, HA; De Azambuja, E; Gingras, I; Gnant, M; Gralow, JR; Harris, L; Holmes, E; Inbar, M; Izquierdo, M; Moreno-Aspitia, A; Naume, B; Nguyen, DH; Piccart, MJ; Tomasello, G; Wolff, AC1
Arima, N; Hasegawa, S; Kai, Y; Katayama, K; Koga, T; Kurashita, K; Mitsuyama, S; Nishimura, R; Ohi, Y; Okumura, Y; Saimura, M; Saito, T; Shimada, K; Tamura, K; Tanaka, M; Tanaka, T; Teraoka, M; Todoroki, H; Toh, U; Toyoshima, S1
Alladin, A; Burwinkel, B; Garcia, M; Gibson, TJ; Havas, KM; Jechlinger, M; Kafkia, E; Klaus, B; Milchevskaya, V; Patil, KR; Pruneri, G; Radic, K; Rotmensz, N; Schneeweiss, A; Sotillo, R; Stolte, J1
Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ1
Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E1
Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L1
Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB1
D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M1
Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T1
Chi, Y; Jiang, ZC1
Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ1
Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Curtis, J; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, SR; Rimel, BJ; Whalen, C1
Gonzalez-Martin, A; Lorusso, D; Pignata, S1
Carty, K; Davidson, S; Dive, C; Jayson, GC; McCartney, E; Paul, J; Rai, D; Simpson, K; Symonds, P; Taylor, S; Tugwood, J; West, C; Zhou, C1
Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS1
Baron, AT; Darcy, KM; Fischer, E; Godwin, AK; Hanjani, P; Leslie, KK; Maihle, NJ; Mannel, RS; Schilder, RJ; Sill, MW; Singh, M; Tewari, KS; Wilken, JA1
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K1
Gandhi, AK; Jagadesan, P; Julka, PK; Kumar, S; Rath, GK; Sharma, DN1
Irifune, K; Ito, R; Miyawaki, S; Sayama, K; Tohyama, M1
Bhatt, VR; Ganti, AK1
Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S1
Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC1
Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L1
Chen, MJ; Li, LY; Wang, MZ; Zhang, L; Zhao, J; Zhong, W1
Aydiner, A; Seyidova, A; Yildiz, I1
Birrer, M; Buss, MK; Dahlberg, SE; Fleming, GF; Ivy, P; Lee, H; Liu, JF; Matulonis, UA; Tolaney, SM; Tyburski, K; Whalen, C; Winer, E1
Chalasani, P; Clausen, C; Dhiwakar, M; Kalapurakal, S; Malone, J; Rao, K; Robbins, KT; Robinson, K; Ronen, O; Shevlin, B1
Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J1
Basaran, G; Benekli, M; Cetin, B; Eralp, Y; Isikdogan, A; Karaca, H; Kucukoner, M; Onur, H; Ozkan, M; Saip, P; Sen, F; Un, O1
Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T1
Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K1
Blackford, AL; Cameron, JL; Choti, MA; Donehower, RC; Edil, BH; Fan, KY; Herman, JM; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, CA; Laheru, DA; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD1
Barlesi, F; Blumenschein, GR; Daniel, DB; Ervin, TJ; Godbert, B; Goldschmidt, JH; Govindan, R; Krzakowski, MJ; Orlov, SV; Patel, PH; Patel, T; Peterson, AC; Phan, SC; Ramlau, RA; Robinet, G; Spigel, DR; Wertheim, MS; Yauch, RL; Yu, W; Zha, J1
Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ1
Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y1
Koyama, N; Uchida, Y1
El Touny, LH; Green, JE; Hoenerhoff, MJ; Khanna, C; Mendoza, A; Vieira, A1
Agboto, VK; Koumangoye, RB; Nangami, GN; Ochieng, J; Sakwe, AM; Thompson, PD1
Bozzi, F; Conca, E; Dagrada, G; Gronchi, A; Manenti, G; Messina, A; Panizza, P; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E1
Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK1
Akashi, A; Funaki, S; Kadota, Y; Nakagiri, T; Okumura, M; Shiono, H; Takeuchi, Y1
Blumenschein, GR; El-Naggar, AK; Glisson, BS; Gonzalez-Angulo, AM; Jakob, JA; Kies, MS; Kupferman, ME; Lee, JJ; Liu, DD1
Li, S; Ren, S; Zhou, C; Zhou, F1
Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK1
Hirai, F; Ichinose, Y; Inamasu, E; Seto, T; Shiraishi, Y; Taguchi, K; Takenaka, T; Takenoyama, M; Takeo, S; Toyokawa, G; Toyozawa, R; Ushijima, C; Yamaguchi, M; Yoshida, T1
Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM1
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S1
Chamberlain, MC; Fadul, CE; Grimm, S; Kim, L; Phuphanich, S; Recht, L; Rosenfeld, S; Zhu, JZ1
He, C; Hong, W; Lou, G; Shao, L; Song, Z; Xie, F; Zhang, B; Zhang, Y; Zheng, L1
Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M1
Carroll, WR; Chung, TK; Clemons, L; Desmond, R; Nabell, L; Rosenthal, EL1
Fasching, PA; Gade, S; Loibl, S; Lübbe, K; Mau, C; Müller, V; Pantel, K; Schem, C; Schwarzenbach, H; Schwedler, K; Steinbach, B; Untch, M; von Minckwitz, G1
Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, H; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, S; Obermayer, L; Quy, P; Rimel, B; Whalen, C; Winer, EP1
Demura, Y; Fujita, Y; Gemma, A; Harada, M; Ishii, Y; Ishimoto, O; Kobayashi, K; Maemondo, M; Matsumoto, Y; Miura, S; Morikawa, N; Okudera, K; Saijo, Y; Sato, I; Takamura, K; Usui, K1
Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H1
Erlichman, C; Flynn, PJ; Juckett, MB; Jumonville, A; LaPlant, B; Mattison, R; Moreno-Aspitia, A1
Lin, J; Wang, L; Xie, B; Xu, T; Zhang, W; Zheng, J; Zhou, J1
Akamatsu, H; Endo, M; Hisamatsu, Y; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Nakashima, K; Ohde, Y; Omori, S; Ono, A; Oyakawa, T; Shukuya, T; Taira, T; Takahashi, K; Takahashi, T; Wakuda, K1
Bourhis, JP; Burtness, B; Cohen, EE; Harrington, KJ; Vermorken, JB1
Batchelor, TT; Beroukhim, R; Betensky, RA; Chheda, MG; Chi, AS; Drappatz, J; Eichler, AF; Gerstner, ER; Hochberg, FH; Norden, AD; Wen, PY; Yang, D1
Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J1
Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL1
Allerton, R; Bidoli, P; Chan, S; Chmielowska, E; Ciruelos, E; Dank, M; DeSilvio, M; Fabi, A; Gori, S; Hornyak, L; Karaszewska, B; Manikhas, A; Margolin, S; Nagi, F; Nusch, A; Parikh, R; Pivot, X; Santillana, S; Semiglazov, V; Swaby, RF; Żurawski, B1
Franckena, M; Kraan, J; Sleijfer, S; van Doorn, L; van Meerten, E; Westermann, A; Wiemer, E1
Schmidt, C1
Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L1
Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP1
Ahn, HK; Cho, EK; Hong, J; Jeong, SH; Kang, SM; Kim, YS; Kyung, SY; Lee, JH; Park, I; Park, J; Park, JW; Shin, DB; Sym, SJ; Woo, HS1
Matsumoto, K; Onda, T; Yaegashi, N1
Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y1
Bouffet, E; DeWire, M; Fisher, P; Foreman, N; Fouladi, M; Gajjar, A; Gilbert, MR; Gilbertson, R; Goldman, S; Hawkins, C; Hwang, EI; Jacobs, C; Khakoo, Y; Liu, D; Rytting, M; Stewart, CF; Turner, DC; Wetmore, C; Yuan, Y1
Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Laenkholm, AV; Larsen, SL; Lykkesfeldt, AE; Rasmussen, BB; Yde, CW1
Argiris, A1
Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB2
Biagi, J; Fleming, GF; Hirte, H; Ivy, SP; Lheureux, S; McGill, S; Morgan, R; Oza, AM; Sugimoto, A; Wang, L1
Ahn, JS; Ahn, MJ; Chang, WJ; Choi, MK; Choi, YL; Do, IG; Hong, JY; Jung, HA; Kim, MJ; Kim, SM; Park, K; Sun, JM1
Killock, D1
Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S1
Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y1
Bourhis, J; Economopoulou, P; Psyrri, A1
Budani, MC; Capone, E; D'Agostino, D; De Cola, A; De Laurenzi, V; Di Ilio, C; Ferracin, M; Lattanzio, R; Negrini, M; Piantelli, M; Sala, G; Stassi, G; Todaro, M; Turdo, A; Veronese, A; Volpe, S1
Bender, D; Darus, CJ; Delmore, JE; Gray, HJ; Hunter, MI; Lankes, HA; Leslie, KK; Mannel, RS; McCourt, CK; Reyes, HD; Rotmensch, J; Samuelson, MI; Schilder, JM; Sill, MW1
Banerjee, A; Boyett, JM; Chi, S; Fahey, F; Fouladi, M; Goldman, S; Jakacki, R; Kieran, MW; Kun, L; Moses, M; Onar-Thomas, A; Packer, RJ; Poussaint, TY; Stewart, CF; Turner, DC; Vajapeyam, S; Wu, S1
Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F1
Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG1
Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F1
Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA1
Banerjee, S; Carty, K; Davidson, S; Dive, C; Flubacher, M; Gourley, C; Hudson, E; Jackson, D; Jankowska, P; Lord, R; McCartney, E; McCormack, M; Paul, J; Powell, M; Rai, D; Reed, N; Symonds, RP; West, CML1
Tewari, KS1
Coarfa, C; Edwards, DP; Hilsenbeck, SG; Holdman, XB; Huang, S; Mo, Q; Pond, A; Rajapakshe, K; Rosen, JM; Welte, T; Zhang, X1
Chen, SC; Goeldner, RG; Harbeck, N; Huang, CS; Hurvitz, S; Im, SA; Im, YH; Jassem, J; Jung, KH; Piccart-Gebhart, M; Ro, J; Shao, Z; Shen, K; Sun, Q; Uttenreuther-Fischer, M; Wojtukiewicz, M; Xu, B; Yeh, DC; Zhang, Q1
Boyle, F; Buzdar, AU; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Horick, N; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Strasser-Weippl, K1
Gajewski, T; Hui, J; McWhirter, E; Oza, A; Pond, G; Quirt, I; Wang, L1
Butman, JA; Fine, HA; Iwamoto, FM; Kreisl, TN; Odia, Y; Shih, JH; Sul, J1
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W1
Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS1
Fukuoka, M; Imamura, F; Inoue, A; Morita, S; Muto, S; Nakagawa, K; Okamoto, I; Seto, T; Yamamoto, N; Yoshida, K1
Clark, E; Cook, A; Eisenhauer, E; Embleton, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Parmar, MKB; Perren, TJ; Raja, F; Rustin, GJS; Stark, D; Swart, AM; Vaughan, M1
Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V1
Specenier, P; Vermorken, J1
Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM1
López-Tarruella, S; Martin, M1
Arcelli, A; Ardizzoni, A; Caravatta, L; Cellini, F; Cilla, S; Cuicchi, D; Deodato, F; DI Fabio, F; Farioli, A; Frezza, G; Fuccio, L; Gambacorta, MA; Giaccherini, L; Guido, A; Macchia, G; Morganti, AG; Picardi, V; Poggioli, G; Valentini, V1
Bonizzi, G; Pruneri, G; Vingiani, A1
Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Grosskurth, SE; Helfrich, BA; Kim, J; Scarborough, HA; Schuller, AG; Tan, AC; Zaberezhnyy, V; Zhang, Z1
Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS1
Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ1
Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T1
Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y1
Heinemann, V; Stemmler, HJ1
Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK1
Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS1
Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D1
Sundermeyer, M; Veeraputhiran, M1
Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F1
Alvarez, RD; Barnes, MN; Estes, JM; Kimball, KJ; Kirby, TO; Koch, KM; Matei, DE; Numnum, TM; Zamboni, WC1
Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W1
Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD1
Aglietta, M; Botti, G; Bottini, A; Clavarezza, M; Danese, S; dei Tos, AP; del Curto, B; Di Bonito, M; Di Palma, S; Donadio, M; Durando, A; Jacomuzzi, ME; Kulka, J; Montemurro, F; Redana, S; Sanna, G; Sapino, A; Valabrega, G; Viale, G1
Im, KC; Kim, SW; Lee, DH; Lee, JS; Moon, DH; Oh, SJ; Ryu, JS; Sohn, HJ; Suh, C; Yang, YJ1
Chen, C; Gaspar, LE; Kavanagh, BD; Kleinschmidt-De Masters, BK; McCammon, R; Schwer, AL; Stuhr, K1
Abrey, LE; Kreisl, TN; Lassman, AB; Lis, E; Mischel, PS; Rosen, N; Scher, HI; Shaffer, D; Teruya-Feldstein, J1
David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY1
Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH1
Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ1
Bunn, PA; Franklin, WA; Hirsch, FR; Kosaka, T; Mitsudomi, T; Nakajima, E; Skokan, M; Varella-Garcia, M; Xavier, AC; Yatabe, Y; Zeng, C1
Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S1
Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE1
Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A1
Dhruva, N; Socinski, MA1
Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M1
Fine, HA; Smith, JA; Yeh, S1
Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY1
Ancukiewicz, M; Batchelor, TT; Chen, PJ; di Tomaso, E; Duda, DG; Jain, RK; Jennings, D; Lahdenranta, J; Sorensen, AG; Wang, M; Wen, PY; Yeo, P; Zhang, WT1
Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ1
Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Norden, AD; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK1
Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Green, J; Hockenhull, J; Macbeth, F; McLeod, C; Proudlove, C; Stevenson, J; Walley, T1
Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R1
Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL1
Batra, RK; Dubinett, SM; Limsukon, A; Soo Hoo, GW; Susanto, I1
Agrawal, A; Cheung, KL; Gee, J; Gutteridge, E; Nicholson, R; Robertson, J1
Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP1
Berkenblit, A; Berlin, S; Campos, S; Cannistra, SA; Hill, M; Horowitz, N; Humphreys, BD; Ivy, P; Krasner, C; Lee, H; Lee, J; Matulonis, UA; Penson, RT; Roche, M; Sullivan, L; Tran, C; Tyburski, K; Whalen, C; Zarwan, C1
Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C1
Ichinose, Y; Maruyama, R; Seto, T; Wataya, H1
Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB1
Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M1
Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L1
Berlin, ST; Humphreys, BD; Ivy, P; Matulonis, UA; Penson, RT; Robinson, ES; Tyburski, K1
Ma, PC; Manson, GV1
Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK1
Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK1
Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S1
Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ1
Burtness, B; Chen, C; Cohen, R; Feigenberg, SJ; Jimeno, A; Kane, M; Lango, M; Mehra, R; Nicolaou, N; Raben, D; Ridge, J; Rusthoven, KE; Song, JI; Swing, R1
Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K1
Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S1
Ancukiewicz, M; Batchelor, TT; Benner, T; Chea, H; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Eichler, AF; Exarhopoulos, A; Gerstner, E; Hochberg, FH; Ivy, P; Jain, RK; Loeffler, JS; Louis, DN; Moses, MA; Plotkin, SR; Sorensen, AG; Wen, PY1
Calles, A; Custodio, A; Pérez-Segura, P1
Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E1
Belani, CP; Gandara, DR; Govindan, R; Ivy, SP; Koczywas, M; Longmate, J; Mack, PC; Ramalingam, SS; Vokes, EE1
Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK1
Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M1
Stupp, R; Tabatabai, G1
Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K1
Katayama, T; Kosaka, T; Matsuo, K; Mitsudomi, T; Sueda, T; Yatabe, Y1
Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ1
Aerts, I; Andreiuolo, F; Chatelut, E; Frappaz, D; Gentet, JC; Geoerger, B; Hargrave, D; Jaspan, T; Le Deley, MC; Leblond, P; Méresse, V; Morland, B; Ndiaye, A; Paoletti, X; Riccardi, R; Saint-Rose, C; Thomas, F; Varlet, P; Vassal, G1
Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A1
Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J1
Andronesi, OC; Auluck, PK; Batchelor, TT; di Tomaso, E; Duda, DG; Fazlollahi, L; Frosch, MP; Hedley-Whyte, ET; Jain, RK; Kamoun, WS; Plotkin, SR; Snuderl, M; Sorensen, AG; Wen, PY1
Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T1
Baxi, S; Carlson, D; Fury, MG; Haque, S; Kelly, KW; Lipson, BL; Pfister, DG; Shen, R; Stambuk, H1
Hanagiri, T; Kuwano, M; Ono, M; Shimokawa, H; Uramoto, H1
Fujita, S; Hata, A; Kaji, R; Katakami, N1
Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B1
Callahan, R; Hurvitz, S1
Andronesi, OC; Batchelor, TT; Catana, C; Jain, RK; Jennings, DL; Kim, H; Ratai, EM; Sorensen, AG1
Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H1
Berardi, S; Caravatta, L; Cellini, N; Deodato, F; Di Filippo, L; Fabrizio, G; Ingrosso, M; Macchia, G; Massaccesi, M; Morganti, AG; Pacelli, F; Padula, GD; Picardi, V; Ridolfini, MP; Tambaro, R; Valentini, V1
Hazama, M; Kim, YH; Niimi, M; Sakamori, Y; Tanaka, S; Yanagihara, K1
Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S1
Cranmer, L; Curiel-Lewandrowski, C; Engelhardt, C; Warneke, J1
Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK1
Bubley, GJ; Carducci, M; Chen, YH; Dipaola, R; Huang, W; Kolesar, J; Liu, G; Pins, M; Stein, M; Wilding, G1
Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ1
Adelstein, DJ; Ives, DI; Rice, TW; Rodriguez, CP; Rybicki, LA1
Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM1
Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N1
Chen, CH; Hsu, WM; Hu, RH; Huang, HC; Huang, J; Huang, MC; Huang, MJ; Lai, HS; Lee, JJ; Lee, PH; Liu, CH; Wu, YM1
Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM1
Ancukiewicz, M; Batchelor, TT; Emblem, KE; Ivy, P; Jain, RK; Jennings, D; Kim, H; Polaskova, P; Sorensen, AG; Wang, M; Wen, PY1
Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C1
Baergen, RN; Boeck, M; Christos, P; Chuang, E; Cigler, T; Cobham, MV; Donovan, D; Jain, S; Lam, C; Lane, ME; Mittal, V; Moore, A; O'Loughlin, J; Rafii, S; Schneider, S; Swistel, A; Vahdat, LT; Ward, MM; Wiener, N1
Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG1
Chen, LQ; Gao, Q; Wang, KN; Wang, WP1
Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M1
Aktolga, S; Blair, EA; Bozeman, J; Cohen, EE; Dancey, JE; Davis, DW; de Souza, JA; Khattri, A; Kozloff, MF; Kunnavakkam, R; Lingen, MW; Nattam, S; Seiwert, TY; Stenson, KM; Vokes, EE; Wong, SJ; Zhang, Y1
Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S1
Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M1
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N1
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE1
Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N1
André, F; Bachelot, T; Campone, M; Frenel, JS; Juin, P1
Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM1
Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S1
Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL1
Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA1
Aiken, RD; Akerley, WA; Beelen, AP; Colman, H; De Groot, JF; Evans, BA; Glantz, M; Grossmann, KF; Jensen, RL; Matsuoko, Y; Olsen, JJ; Olson, JJ; Yu, M1
Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ1
Lin, NU; Vaz-Luis, I; Winer, EP1
Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S1
Fine, HA; Iwamoto, FM; Kreisl, TN; McNeill, KA; Shih, J; Sul, J1
Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R1
Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R1
Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S1
Hirami, Y; Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yasuda, K; Yukawa, T1
Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X1
Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM1
Kujala, PM; Murtola, TJ; Tammela, TL1
Chen, EX; Haider, MA; Halford, R; Hotte, SJ; Ivy, SP; Kollmannsberger, C; Mackenzie, MJ; Moore, MJ; Mukherjee, SD; Murray, N; Sridhar, SS; Tannock, IF; Wang, L1
Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY1
Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H1
Glisson, BS1
Botwood, N; James, RD; Price, P; Vernon, CC1
Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE1
Johnson, DH1
Barrow, D; Gee, JM; Hutcheson, I; Knowlden, J; Madden, TA; McClelland, R; Nicholson, RI1
Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ1
Katz, A; Zalewski, P1
Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA1
Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H1
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE1
Argiris, A; Mittal, N1
Aderka, D; Levitt, ML; Pfeffer, MR1
Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS1
del Giglio, A; Ito, C1
Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC1
Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H1
Dawson, NA; Dorsey, B; Guo, C; Hussain, A; Smoot, J; Wong, J; Zak, R1
Aikawa, A; Hanawa, Y; Hashizume, M; Itou, S; Katou, K; Kidokoro, T; Kimura, B; Okano, Y; Takano, T; Takaoka, K; Tokimitsu, S; Uchikado, M; Yagi, M; Yamagishi, M1
Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG1
Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y1
Yang, CH1
Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A1
Blackwell, KL; Burris, HA; Dees, EC; Dowlati, A; Ellis, MJ; Harris, JL; Hurwitz, HI; Jones, SF; Koch, KM; Mangum, S; Marcom, PK; O'Neil, B; Overmoyer, B; Smith, DA; Spector, NL; Stead, A1
Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H1
Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T1
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE1
Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK1
Boshoff, C; Falzon, M; Lai, CS; Lee, SM1
Bolzicco, G; Coco, C; Dalla Palma, M; De Paoli, A; Di Russo, A; Doglietto, GB; Gambacorta, MA; Mohiuddin, M; Morganti, AG; Rossi, C; Valentini, V; Valvo, F1
Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D1
Axelson, J; Breen, TE; Einhorn, LH; Estes, D; Govindan, R; Hanna, NH; Moore, AM; Vinson, J; Yu, M1
A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M1
Hennemann, B1
Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX1
Mitra, SS; Simcock, R1
Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F1
Aksoy, S; Altundag, K; Dincer, M; Kilickap, S1
Cohen, EE1
Laurie, SA; Licitra, L1
Charoentum, C1
Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O1
Hanagiri, T; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K1
Debus, J; Hof, H; Welzel, T1
Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M1
Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ1
Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Franceschi, E; Grosso, D; Lonardi, S; Magrini, E; Pession, A; Scopece, L; Tallini, G; Tosoni, A; Urbini, B1
Kohno, H; Maehara, Y; Mori, D; Shoji, F; Yamasaki, F; Yano, T; Yoshino, I1
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C1
Agulnik, M; Chen, EX; Chen, H; Chen, S; da Cunha Santos, G; Dancey, J; Dos Reis, PP; Hedley, D; Ho, J; Kamel-Reid, S; Marrano, P; Nicklee, T; Pond, GR; Shyr, Y; Siu, LL; Soulieres, D; Squire, JA; Tsao, MS; Winquist, E1
Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F1
Jackman, D; Jänne, PA; Johnson, BE1
Goss, PE; Moy, B1
Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H1
Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E1
Ahuja, A; Chan, AT; Hui, EP; Kam, M; King, A; Leung, SF; Lo, YM; Ma, B; Mo, F; Mok, T; To, KF; Zee, B1
Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A1
Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S1
Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okuda, K; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H1
Hanaoka, T; Hayano, T; Okada, M; Sone, S; Yamaguchi, S1
Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX1
Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L1
Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, K; Schwer, AL; Stuhr, K1
Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P1
Okagawa, T; Suyama, M; Uchida, T1
Chen, EX; Chia, S; Colevas, AD; Hotte, SJ; Johnson, C; Pond, GR; Schwarz, JK; Siu, LL; Synold, TW; Tang, PA; Vasist, LS; Winquist, E1
Bell, DW; Brannigan, BW; Morabito, A; Moscato, M; Normanno, N; Zampa, G1
Higashiyama, M; Kato, K; Kodama, K; Koizumi, K; Maeda, J; Oda, K; Okami, J; Orita, N; Taniguchi, K1
Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ1
Au, GK; Chua, DT; Nicholls, J; Sham, JS; Wei, WI; Wong, MP1
Ano, T; Miyazaki, K; Nakazawa, K; Ohtsuka, M; Satoh, H1
Duell, T; Poellinger, B; von Pawel, J; Wagner, H1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E1
Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S1
Faoro, L; Fleming, GF; Friberg, G; Kasza, K; Morgan, RJ; Nimeiri, HS; Oza, AM; Salgia, R; Stadler, WM; Vokes, EE1
Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT1
Chamness, GC; Chang, JC; Gutierrez, C; Hilsenbeck, SG; Huang, J; Lewis, MT; Li, X; Osborne, CK; Pavlick, A; Rosen, J; Wong, H; Wu, MF; Zhang, X1
Fujiwara, Y; Hotta, K; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H1
Azab, M; Cassidy, J; Earl, HM; Gore, ME; Mansi, J; Seymour, L; Tattersall, M1
Clarke, SJ; Dalley, D; Davidson, YE; Green, M; Mitchell, PL; Olver, I; Rischin, D; Zalcberg, J1
Belpomme, D; Clendeninn, N; Domenge, C; Humblet, Y; Johnston, A; Kelly, C; Penning, C; Pivot, X; Ruxer, R; Schneider, M; Stern, J; Tortochaux, J; Wadler, S1
Bakanauskas, VJ; Bernhard, EJ; Cerniglia, GJ; Feldman, MD; Goldsmith, JD; Gupta, AK; Machtay, M; McKenna, WG; Mick, R; Muschel, RJ; Rosenthal, DI; Weber, CN; Weber, RS1
Angelopoulou, A; Fotia, M; Kontos, A; Kosmas, C; Koufos, Ch; Sougioultzis, S; Soulla, M; Tsavaris, N; Vadiaka, M; Vrizidis, N1
Aparicio, J; Camps, C; Escudero, P; Feliu, J; García Girón, C; González Barón, M; Mel, JR; Menéndez, D; Rodriguez, MR; Sánchez, JJ1

Reviews

30 review(s) available for quinazolines and Local Neoplasm Recurrence

ArticleYear
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-
    Advances in therapy, 2022, Volume: 39, Issue:4

    Topics: Benzamides; Biphenyl Compounds; Child, Preschool; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Lymphoma, Follicular; Morpholines; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Purines; Pyridones; Pyrimidines; Quinazolines; Quinazolinones; Risk

2022
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Drugs, 2020, Volume: 80, Issue:17

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2020
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    The Cochrane database of systematic reviews, 2021, 03-04, Volume: 3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult

2021
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    The Cochrane database of systematic reviews, 2018, 10-16, Volume: 10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic

2018
HER2-positive metastatic breast cancer: a changing scenario.
    Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1

    Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab

2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids

2015
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015

    Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational

2015
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
    Medicine, 2016, Volume: 95, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma

2016
Afatinib in squamous cell carcinoma of the head and neck.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:9

    Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2016
Emerging Therapeutic Options for HER2-Positive Breast Cancer.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cancer Vaccines; Female; Humans; Immunotherapy; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab

2016
Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients.
    Current opinion in oncology, 2016, Volume: 28, Issue:6

    Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2016
[Oncology 2008].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2008
Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2

2009
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
    Der Nervenarzt, 2010, Volume: 81, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A

2010
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
    Current opinion in obstetrics & gynecology, 2011, Volume: 23, Issue:1

    Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab

2011
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles

2012
[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
    Bulletin du cancer, 2012, Volume: 99, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab

2012
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Receptors, Estrogen; Treatment Outcome

2013
Recurrent small cell lung cancer: update.
    Seminars in oncology, 2003, Volume: 30, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Gefitinib; Humans; Immunotoxins; Lung Neoplasms; Neoplasm Recurrence, Local; Oligonucleotides, Antisense; Prognosis; Quinazolines; Thionucleotides

2003
Gefitinib (Iressa) trials in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome

2003
The biology of antihormone failure in breast cancer.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2003
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
    British journal of cancer, 2003, Volume: 89 Suppl 2

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Quinazolines

2003
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
    Clinical lung cancer, 2004, Volume: 5, Issue:6

    Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids

2004
[Palliative chemotherapy of head and neck cancer: present status and future development].
    Laryngo- rhino- otologie, 2006, Volume: 85, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine

2006
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome

2006
Systemic therapy in the palliative management of advanced salivary gland cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab

2006
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha

2006
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases

2007
Lapatinib-associated toxicity and practical management recommendations.
    The oncologist, 2007, Volume: 12, Issue:7

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2

2007
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab

2008

Trials

175 trial(s) available for quinazolines and Local Neoplasm Recurrence

ArticleYear
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Cancer medicine, 2021, Volume: 10, Issue:20

    Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Treatment Outcome; Young Adult

2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    Future oncology (London, England), 2021, Volume: 17, Issue:34

    Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2

2021
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecologic oncology, 2022, Volume: 164, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines

2022
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-01, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Lapatinib; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab; United Kingdom

2022
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Blood advances, 2022, 09-27, Volume: 6, Issue:18

    Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinazolines

2022
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
    International journal of hematology, 2023, Volume: 117, Issue:1

    Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quinazolines

2023
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
    Oral oncology, 2019, Volume: 97

    Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Adherence and Compliance; Treatment Outcome

2019
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherap
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:1

    Topics: Adult; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis

2021
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:4

    Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Pyrimidines; Quinazolines; Treatment Outcome

2021
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
    BMJ open, 2021, 01-15, Volume: 11, Issue:1

    Topics: Clinical Trials, Phase II as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Randomized Controlled Trials as Topic

2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
    ESMO open, 2021, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines

2021
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
    Cancer, 2017, Jul-15, Volume: 123, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction

2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    Journal of the National Cancer Institute, 2017, 08-01, Volume: 109, Issue:8

    Topics: Antineoplastic Agents; Axilla; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lapatinib; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab; Tumor Burden

2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10

    Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck

2017
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Hypertension; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum Compounds; Progression-Free Survival; Quinazolines; Response Evaluation Criteria in Solid Tumors; Time Factors

2019
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult

2019
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
    Journal for immunotherapy of cancer, 2019, 07-25, Volume: 7, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms

2019
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate

2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome

2013
Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:4

    Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Female; Gefitinib; Humans; India; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Uterine Cervical Neoplasms

2013
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
    Oral oncology, 2013, Volume: 49, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids

2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Aug-01, Volume: 19, Issue:15

    Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms

2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated

2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:14

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Carcinoma, Ovarian Epithelial; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Tablets; Treatment Outcome

2013
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome

2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; International Agencies; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate

2013
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Time Factors; Turkey; Vinblastine; Vinorelbine

2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-10, Volume: 31, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome

2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
    Clinical lung cancer, 2014, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate

2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Neuro-oncology, 2014, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult

2014
Phase II study of gefitinib in patients with advanced salivary gland cancers.
    Head & neck, 2015, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome

2015
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome

2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate

2014
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
    Journal of neuro-oncology, 2014, Volume: 118, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult

2014
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
    BMC cancer, 2014, Jun-28, Volume: 14

    Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck

2014
Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients.
    Annals of surgical oncology, 2014, Volume: 21, Issue:13

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate

2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome

2014
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retreatment; Treatment Outcome

2014
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome

2014
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate

2015
Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil.
    Oncology research and treatment, 2014, Volume: 37, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome

2014
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized control
    Trials, 2014, Nov-29, Volume: 15

    Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Protocols; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Time Factors; Treatment Outcome

2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
    Journal of neuro-oncology, 2015, Volume: 121, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Sirolimus

2015
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2015
Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.
    The oncologist, 2015, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Lapatinib; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Uterine Cervical Neoplasms

2015
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
    Cancer biology & therapy, 2015, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2015
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
    Cancer research and treatment, 2016, Volume: 48, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines

2016
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
    Journal of neuro-oncology, 2015, Volume: 123, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Drug Resistance, Neoplasm; Ependymoma; Female; Follow-Up Studies; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate; Tissue Distribution; Young Adult

2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2015
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
    Gynecologic oncology, 2015, Volume: 138, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines

2015
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines

2015
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
    Cancer investigation, 2015, Volume: 33, Issue:6

    Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines

2015
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecologic oncology, 2015, Volume: 138, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines

2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2015, Volume: 31, Issue:9

    Topics: Administration, Oral; Adolescent; Biological Availability; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic; Time Factors; Young Adult

2015
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
    Oncotarget, 2015, Oct-06, Volume: 6, Issue:30

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Quinazolines; Rectal Neoplasms; Risk Factors; Thiophenes; Time Factors; Treatment Outcome

2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
    Clinical breast cancer, 2016, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab

2016
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:15

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms

2015
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:3

    Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine

2016
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 56

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Precision Medicine; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors; Treatment Outcome

2016
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
    Investigational new drugs, 2016, Volume: 34, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A

2016
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
    CNS oncology, 2016, Volume: 5, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Quinazolines

2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet (London, England), 2016, Mar-12, Volume: 387, Issue:10023

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Quinazolines; Treatment Outcome

2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab

2016
Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.
    Anticancer research, 2016, Volume: 36, Issue:8

    Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Thiophenes

2016
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
    Oncology research and treatment, 2016, Volume: 39, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome

2016
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
    Journal of neuro-oncology, 2008, Volume: 90, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines

2008
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-10, Volume: 26, Issue:26

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines

2008
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
    Clinical lung cancer, 2008, Volume: 9, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design

2008
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Gynecologic oncology, 2008, Volume: 111, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines

2008
[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Smoking; Survival Rate

2008
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide

2008
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
    International journal of radiation oncology, biology, physics, 2009, Apr-01, Volume: 73, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Tumor Burden; Young Adult

2009
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
    Journal of neuro-oncology, 2009, Volume: 92, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Gefitinib; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Sirolimus

2009
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-10, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide

2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome

2009
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome

2009
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2

2010
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2010, Volume: 96, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome

2010
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
    Journal of neuro-oncology, 2010, Volume: 96, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Tomography, X-Ray Computed

2010
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Oral oncology, 2009, Volume: 45, Issue:10

    Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome

2009
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome

2009
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
    International journal of cancer, 2010, Apr-15, Volume: 126, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

2010
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome

2009
Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2

2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 69, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines

2010
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome

2010
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
    Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:3

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Blood Pressure; Carcinoma; Chi-Square Distribution; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome

2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Neuro-oncology, 2010, Volume: 12, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult

2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
    Neuro-oncology, 2010, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution

2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome

2010
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2010, Nov-15, Volume: 78, Issue:4

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retreatment; Treatment Outcome

2010
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Anticancer research, 2010, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult

2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-10, Volume: 28, Issue:17

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Young Adult

2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome

2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; United States

2010
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
    Neuro-oncology, 2010, Volume: 12, Issue:10

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines

2010
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
    Gynecologic oncology, 2010, Volume: 118, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines

2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Neuro-oncology, 2010, Volume: 12, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution

2010
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
    Neuro-oncology, 2011, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Brain Stem Neoplasms; Child; Child, Preschool; Erlotinib Hydrochloride; Female; Glioma; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Therapies, Investigational; Tissue Distribution; Treatment Outcome; Young Adult

2011
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    International journal of radiation oncology, biology, physics, 2012, Jan-01, Volume: 82, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult

2012
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Adult; Aged; Benzodioxoles; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Young Adult

2011
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate

2012
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
    Cancer research, 2011, Jun-01, Volume: 71, Issue:11

    Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult

2011
Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study.
    American journal of clinical oncology, 2012, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Quinazolines; Rectal Neoplasms; Thiophenes; Treatment Outcome

2012
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
    Trials, 2011, May-12, Volume: 12

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Research Design; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Young Adult

2011
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
    Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

2011
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
    Clinical lung cancer, 2011, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult

2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
    Urologic oncology, 2013, Volume: 31, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins

2013
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Quinazolines; Survival Analysis; Treatment Outcome

2012
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
    British journal of cancer, 2011, Sep-27, Volume: 105, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome

2011
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
    Gynecologic oncology, 2012, Volume: 124, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines

2012
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
    Cancer research, 2012, Jan-15, Volume: 72, Issue:2

    Topics: Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate

2012
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
    Breast cancer research and treatment, 2012, Volume: 132, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Count; Cohort Studies; Dasatinib; Female; Hemangioblasts; Hematopoietic Stem Cells; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Thiazoles; Trastuzumab; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2012
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
    Head & neck, 2012, Volume: 34, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult

2012
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome

2012
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck

2012
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
    Journal of neuro-oncology, 2012, Volume: 108, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult

2012
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
    Pediatric blood & cancer, 2013, Volume: 60, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases

2013
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral oncology, 2012, Volume: 48, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin

2012
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome

2013
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate

2013
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
    Gynecologic oncology, 2012, Volume: 127, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome

2012
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
    Journal of neuro-oncology, 2012, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution

2012
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
    Journal of neuro-oncology, 2012, Volume: 110, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cohort Studies; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution

2012
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
    Journal of experimental therapeutics & oncology, 2012, Volume: 10, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence

2012
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Neuro-oncology, 2012, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Young Adult

2012
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    Acta neurochirurgica, 2013, Volume: 155, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A

2013
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires

2012
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis

2013
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
    Journal of neurology, 2013, Volume: 260, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide

2013
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
    Neuro-oncology, 2013, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution

2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Contrast Media; Demography; Disease Progression; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome

2013
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4

    Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides

2013
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Oral oncology, 2013, Volume: 49, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins

2013
Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Rectal Neoplasms; Thiophenes

2003
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome

2003
Phase II trial of gefitinib in recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome

2004
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines

2004
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome

2004
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome

2004
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-10, Volume: 23, Issue:11

    Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA; Sensitivity and Specificity; Sex Factors; Survival Analysis

2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-10, Volume: 23, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Quinazolines; Receptor, ErbB-2; Safety; Treatment Outcome

2005
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A

2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis

2005
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Pain Management; Quinazolines; Radiotherapy; Rectal Neoplasms; Thiophenes; Treatment Failure

2006
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
    Neuro-oncology, 2006, Volume: 8, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome

2006
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 52, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome

2006
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer.
    British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis

2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis

2006
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Thiophenes

2006
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
    Cancer cell, 2007, Volume: 11, Issue:1

    Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis

2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Cancer, 2007, Apr-01, Volume: 109, Issue:7

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome

2007
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    British journal of cancer, 2007, Apr-10, Volume: 96, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligodendroglioma; Quinazolines; Survival Rate; Treatment Outcome

2007
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-01, Volume: 13, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib

2007
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16

    Topics: Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Skin

2007
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Gefitinib; Humans; Lactones; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proteomics; Quinazolines; Sulfones; Survival Rate; Treatment Outcome

2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome

2007
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1

    Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; DNA, Viral; ErbB Receptors; Female; Gefitinib; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Radiography; Survival

2008
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome

2007
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
    Investigational new drugs, 2008, Volume: 26, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome

2008
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    International journal of radiation oncology, biology, physics, 2008, Mar-15, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dose Fractionation, Radiation; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Mental Status Schedule; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Treatment Outcome

2008
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms

2008
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Investigational new drugs, 2008, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Gene Expression; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kinesins; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Treatment Outcome

2008
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms

2008
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
    Head & neck, 2008, Volume: 30, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome

2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines

2008
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
    Gynecologic oncology, 2008, Volume: 110, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Selection; Peritoneal Neoplasms; Quinazolines; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2008
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 62, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan

2008
A phase II study of Tomudex in relapsed epithelial ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Quinazolines; Remission Induction; Thiophenes

1995
Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome

2000
Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Diarrhea; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Thymidylate Synthase; Treatment Outcome

2001
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Chromones; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; ras Proteins; Signal Transduction

2002
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
    Investigational new drugs, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Quinazolines; Thiophenes; Thymidylate Synthase

2002
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Sex Factors; Survival Analysis; Thiophenes; Treatment Outcome

2002

Other Studies

131 other study(ies) available for quinazolines and Local Neoplasm Recurrence

ArticleYear
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.
    BMC infectious diseases, 2021, Sep-23, Volume: 21, Issue:1

    Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Humans; Liver Transplantation; Mutation; Neoplasm Recurrence, Local; Quinazolines

2021
Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:4

    Topics: Acetates; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines

2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19

    Topics: Adolescent; Adult; Bevacizumab; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Indoles; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines

2022
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations.
    Contrast media & molecular imaging, 2022, Volume: 2022

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines

2022
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.
    Anti-cancer drugs, 2020, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Thiophenes

2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
    ESMO open, 2020, Volume: 5, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Italy; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome

2020
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:7

    Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Renal Insufficiency

2021
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
    Blood advances, 2021, 02-09, Volume: 5, Issue:3

    Topics: Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines

2021
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:10

    Topics: Aged; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Protein Kinase Inhibitors; Quinazolines

2021
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Oncology, 2017, Volume: 93, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult

2017
Metabolic shifts in residual breast cancer drive tumor recurrence.
    The Journal of clinical investigation, 2017, Jun-01, Volume: 127, Issue:6

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lipid Metabolism; Metabolic Networks and Pathways; Mice; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxidative Stress; Progesterone; Quinazolines; Reactive Oxygen Species; Transcriptome; Xenograft Model Antitumor Assays

2017
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    The oncologist, 2017, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan

2017
Gefitinib Delays NSCLC Recurrence After Surgery.
    Cancer discovery, 2017, Volume: 7, Issue:7

    Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines

2017
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:10

    Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab

2017
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:3

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy

2018
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
    Oncology research, 2018, Aug-23, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate

2018
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A

2018
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, Aug-23, Volume: 40, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes

2018
Chemotherapy-free treatments: are we ready for prime time?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4

    Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time

2019
Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
    International wound journal, 2014, Volume: 11, Issue:5

    Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pressure Ulcer; Quinazolines; Wound Healing

2014
Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.
    Oral oncology, 2013, Volume: 49, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus

2013
Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
    Chinese medical journal, 2013, Volume: 126, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies

2013
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult

2013
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome

2013
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
    Pancreas, 2013, Volume: 42, Issue:7

    Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis

2013
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2013, Nov-01, Volume: 87, Issue:3

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smad4 Protein; Treatment Outcome

2013
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate

2013
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate

2013
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays

2014
Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
    Molecular cancer, 2013, Dec-19, Volume: 12, Issue:1

    Topics: Annexin A6; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Lysosomes; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proteolysis; Quinazolines

2013
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
    Neuro-oncology, 2014, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Chordoma; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
Does gefitinib have effects on EGFR mutation-positive thymoma? -Case report of thymoma recurrence.
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2014, Volume: 20 Suppl

    Topics: Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Reoperation; Thoracic Surgery, Video-Assisted; Thymoma; Thymus Neoplasms

2014
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines; Radiography; Treatment Outcome

2014
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines

2014
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate

2014
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014, Volume: 17, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate

2014
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Breast cancer research and treatment, 2014, Volume: 147, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Female; Follow-Up Studies; Humans; Lapatinib; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Translational Research, Biomedical; Trastuzumab

2014
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
    International journal of clinical oncology, 2015, Volume: 20, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies

2015
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
    General thoracic and cardiovascular surgery, 2016, Volume: 64, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines

2016
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult

2014
Cediranib aims for a comeback.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss

2015
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines

2015
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    BMC cancer, 2015, Apr-08, Volume: 15

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aurora Kinase B; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mitosis; Neoplasm Recurrence, Local; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Survival Analysis; Tamoxifen

2015
EGFR inhibition for recurrent or metastatic HNSCC.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines

2015
Head and neck cancer: second-line afatinib shows promise.
    Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines

2015
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
    International journal of clinical oncology, 2015, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome

2015
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
    Cell death & disease, 2015, Jul-16, Volume: 6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Transcription Factors; Trastuzumab; Tumor Suppressor Proteins

2015
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines

2016
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
    Oncotarget, 2015, Oct-20, Volume: 6, Issue:32

    Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome

2015
Clinical implications for cediranib in advanced cervical cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:15

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines; Uterine Cervical Neoplasms

2015
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
    Breast cancer research : BCR, 2015, Nov-18, Volume: 17

    Topics: Animals; Breast Neoplasms; Collagen; ErbB Receptors; Female; Lapatinib; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tenascin; Up-Regulation; Wnt1 Protein

2015
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
    Breast cancer research and treatment, 2016, Volume: 155, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab

2016
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate

2016
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
    Cancer, 2016, 08-01, Volume: 122, Issue:15

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2016
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Mar-15, Volume: 23, Issue:6

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasm Recurrence, Local; Quinazolines; Tankyrases; Wnt Signaling Pathway; Xenograft Model Antitumor Assays

2017
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Pharmacological research, 2017, Volume: 115

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase

2017
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
    Chemotherapy, 2017, Volume: 62, Issue:3

    Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome

2017
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Oncology research and treatment, 2017, Volume: 40, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome

2017
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
    Nature clinical practice. Urology, 2008, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms

2008
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
    Clinical lung cancer, 2008, Volume: 9, Issue:4

    Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed

2008
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Clinical breast cancer, 2008, Volume: 8, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab

2008
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorine Radioisotopes; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; ROC Curve; Thymidine; Time; Tomography, X-Ray Computed

2008
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
    Journal of neuro-oncology, 2009, Volume: 92, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis

2009
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
    Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking

2009
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:3

    Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Genes, ras; Genome; Humans; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Probability; Prognosis; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Survival Analysis

2009
A case report of thyroid cancer showing a remarkable effect of gefitinib.
    Auris, nasus, larynx, 2009, Volume: 36, Issue:5

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2009
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed

2009
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
    Cornea, 2009, Volume: 28, Issue:6

    Topics: Astrocytoma; Brain Neoplasms; Cellulase; Corneal Diseases; Corneal Opacity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ointments; Piperidines; Quinazolines; Retrospective Studies; Sodium Chloride; Vascular Endothelial Growth Factor Receptor-2

2009
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Survival Rate; Young Adult

2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
    Cancer research, 2009, Jul-01, Volume: 69, Issue:13

    Topics: Antineoplastic Agents; Biomarkers; Blood Volume; Brain Neoplasms; Collagen; Disease-Free Survival; Glioblastoma; Hematologic Tests; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Survival Rate

2009
Erlotinib for the treatment of relapsed non-small cell lung cancer.
    Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 1

    Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical

2009
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.
    Chest, 2009, Volume: 136, Issue:3

    Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides

2009
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome

2010
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.
    Anticancer research, 2009, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Treatment Failure

2009
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:12

    Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases

2009
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
    Clinical lung cancer, 2010, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome

2010
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
    Acta medica Okayama, 2010, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids

2010
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic

2010
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:4

    Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy

2010
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
    The Journal of thoracic and cardiovascular surgery, 2010, Volume: 140, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome

2010
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
    Surgical oncology, 2010, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome

2010
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
    Clinical drug investigation, 2011, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines

2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
    Cancer research, 2011, Jan-01, Volume: 71, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Glioblastoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Recurrence, Local; Quinazolines

2011
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
    Surgery today, 2011, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines

2011
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cadherins; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibronectins; gamma Catenin; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins

2011
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome

2011
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure

2011
Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:1

    Topics: Axilla; Biopsy, Needle; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Shoulder; Skin Neoplasms; Treatment Outcome

2011
Erlotinib-induced rash spares previously irradiated skin.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:8

    Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed

2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Clinical lung cancer, 2012, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome

2012
Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire international, 2011, Volume: 20, Issue:120

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines

2011
Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
    Cancer research, 2011, Dec-01, Volume: 71, Issue:23

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Glycosylation; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mucins; N-Acetylgalactosaminyltransferases; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polypeptide N-acetylgalactosaminyltransferase; Quinazolines; RNA, Messenger

2011
Pneumocystis jiroveci Pneumonia in an Atypical Host.
    Clinical breast cancer, 2012, Volume: 12, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination

2012
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
    World journal of surgical oncology, 2012, Jan-17, Volume: 10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate

2012
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult

2012
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids

2012
Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
    Targeted oncology, 2013, Volume: 8, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies

2013
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    BMC cancer, 2013, Jan-18, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies

2013
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
    The Prostate, 2013, Volume: 73, Issue:9

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cohort Studies; Disease-Free Survival; Dutasteride; Finasteride; Finland; Humans; Kallikreins; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Sulfonamides; Survival Rate; Tamsulosin

2013
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis

2004
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids

2004
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2004, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate

2004
Gefitinib in recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-01, Volume: 22, Issue:13

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results

2004
Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
    Sao Paulo medical journal = Revista paulista de medicina, 2004, May-06, Volume: 122, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines

2004
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
    Investigational new drugs, 2005, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate

2005
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome

2005
[A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Postoperative Period; Quality of Life; Quinazolines; Respiratory Insufficiency

2005
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    The New England journal of medicine, 2005, Feb-24, Volume: 352, Issue:8

    Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA

2005
Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
    Journal of the Chinese Medical Association : JCMA, 2005, Volume: 68, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome

2005
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
    Proceedings of the National Academy of Sciences of the United States of America, 2005, May-24, Volume: 102, Issue:21

    Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured

2005
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics

2005
Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome

2005
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
    Thorax, 2006, Volume: 61, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome

2006
Erlotinib induced skin rash spares skin in previous radiotherapy field.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall

2006
Gefitinib efficacy in relapsed small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome

2006
Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome

2006
Resistance to gefitinib.
    International journal of clinical oncology, 2006, Volume: 11, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines

2006
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chordoma; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Spinal Neoplasms; Treatment Outcome

2006
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Care; Quinazolines; Treatment Failure

2008
EGFR exon 20 insertion mutation in Japanese lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2007, Volume: 58, Issue:3

    Topics: Aged; Asian People; Base Sequence; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Quinazolines; Tomography Scanners, X-Ray Computed

2007
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 59, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome

2008
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Smoking

2008
[An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:10

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines

2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate

2007
[A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survivors

2007
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Time Factors

2008
Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
    Oncology, 2007, Volume: 72, Issue:3-4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis

2007
Late fatal recurrence in gefitinib-treated NSCLC patients.
    Tuberkuloz ve toraks, 2007, Volume: 55, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tomography, X-Ray Computed

2007
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.
    Onkologie, 2008, Volume: 31, Issue:3

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome

2008
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Journal of the National Cancer Institute, 2008, May-07, Volume: 100, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design

2008
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2008, Volume: 62, Issue:2

    Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Smoking; Survival Analysis

2008